MX343837B - Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida. - Google Patents

Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.

Info

Publication number
MX343837B
MX343837B MX2014005635A MX2014005635A MX343837B MX 343837 B MX343837 B MX 343837B MX 2014005635 A MX2014005635 A MX 2014005635A MX 2014005635 A MX2014005635 A MX 2014005635A MX 343837 B MX343837 B MX 343837B
Authority
MX
Mexico
Prior art keywords
triazol
benzamide
receptor antagonists
orexin receptor
amide derivatives
Prior art date
Application number
MX2014005635A
Other languages
English (en)
Other versions
MX2014005635A (es
Inventor
Boss Christoph
Bolli Martin
Brotschi Christine
Heidmann Bibia
Sifferlen Thierry
T Williams Jodi
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2014005635A publication Critical patent/MX2014005635A/es
Publication of MX343837B publication Critical patent/MX343837B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención se refiere a derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-iI)picolinami da de la fórmula (I): (ver Fórmula) en donde Ar1, Q y R1 a R5 se definen según lo referido en la descripción; a su preparación; a sus sales farmacéuticamente aceptables; y a su uso como productos farmacéuticos; a composiciones farmacéuticas que contienen uno o más compuestos de la fórmula (I); y en especial, a su uso como antagonistas del receptor de orexina.
MX2014005635A 2011-11-08 2012-11-07 Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida. MX343837B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011054976 2011-11-08
PCT/IB2012/056218 WO2013068935A1 (en) 2011-11-08 2012-11-07 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists

Publications (2)

Publication Number Publication Date
MX2014005635A MX2014005635A (es) 2014-06-23
MX343837B true MX343837B (es) 2016-11-24

Family

ID=47258050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005635A MX343837B (es) 2011-11-08 2012-11-07 Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.

Country Status (28)

Country Link
US (1) US9150566B2 (es)
EP (1) EP2776430B1 (es)
JP (1) JP5718535B2 (es)
KR (1) KR101676930B1 (es)
CN (1) CN103917538B (es)
AR (1) AR088692A1 (es)
AU (1) AU2012335194B2 (es)
BR (1) BR112014010617B1 (es)
CA (1) CA2846568C (es)
CL (1) CL2014000659A1 (es)
CY (1) CY1117638T1 (es)
DK (1) DK2776430T3 (es)
EA (1) EA024106B1 (es)
ES (1) ES2572703T3 (es)
HK (1) HK1199022A1 (es)
HR (1) HRP20160678T1 (es)
HU (1) HUE029239T2 (es)
IL (1) IL232462A (es)
IN (1) IN2014CN04127A (es)
MX (1) MX343837B (es)
MY (1) MY167791A (es)
PL (1) PL2776430T3 (es)
SG (1) SG11201401665WA (es)
SI (1) SI2776430T1 (es)
TW (2) TWI565703B (es)
UA (1) UA112317C2 (es)
WO (1) WO2013068935A1 (es)
ZA (1) ZA201404189B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
WO2013119639A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
DK3077389T3 (da) 2013-12-03 2017-11-13 Idorsia Pharmaceuticals Ltd Krystallinsk form af (s)-(2-(6-chlor-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanon og dens anvendelse som orexinreceptorantagonister
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
US9914721B2 (en) 2013-12-04 2018-03-13 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
CN105814042B (zh) * 2013-12-13 2018-09-28 大正制药株式会社 噁嗪烷化合物的晶形及其制造方法
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
JP6323886B2 (ja) * 2014-05-16 2018-05-16 国立大学法人 東京大学 うつ治療剤
WO2016025669A1 (en) 2014-08-13 2016-02-18 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
WO2016095205A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
CN104557744B (zh) * 2014-12-23 2017-04-12 广东东阳光药业有限公司 一种三氮唑化合物的制备方法
CN106749269B (zh) 2015-11-23 2019-01-04 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN109219606B (zh) 2016-02-12 2021-10-01 阿斯利康(瑞典)有限公司 食欲素受体调节剂的卤素取代的哌啶
CN110612291B (zh) 2017-05-03 2024-02-13 爱杜西亚药品有限公司 2-([1,2,3]三唑-2-基)-苯甲酸衍生物的制备
WO2020099511A1 (en) * 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
GB201901142D0 (en) * 2019-01-28 2019-03-20 Heptares Therapeutics Ltd OX1 Antagonists
CA3206675A1 (en) 2021-02-02 2022-08-11 Markus Von Raumer A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone
TW202400149A (zh) * 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130432A (en) 1990-12-21 1992-07-14 Syntex (U.S.A.) Inc. Process for preparing cyclic amines and intermediate products thereof
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
AU2002341123A1 (en) 2001-05-05 2002-11-18 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
WO2003002561A1 (en) * 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
SI1751111T1 (sl) 2004-03-01 2015-04-30 Actelion Pharmaceuticals Ltd. Substituirani 1,2,3,4-tetrahidroizokinolinski derivati
MX2008011647A (es) 2006-03-15 2008-09-22 Actelion Pharmaceuticals Ltd Derivados de tetrahidroisoquinolina para mejorar la funcion de la memoria.
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
JP2010540429A (ja) 2007-09-24 2010-12-24 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
CA2739916A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
AU2009307916A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
JP2012506374A (ja) * 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
EA201170742A1 (ru) 2008-12-02 2012-01-30 Глэксо Груп Лимитед Производные n-{[(1r,4s,6r)-3-(2-пиридинилкарбонил)-3-азабицикло[4.1.0]гепт-4-ил]метил}-2-гетероариламинов и их применения
EA201170741A1 (ru) 2008-12-02 2011-12-30 Глэксо Груп Лимитед Производные n-{[(1r,4s,6r)-3-(2-пиридинилкарбонил)-3-азабицикло[4.1.0]гепт-4-ил]метил}-2-гетероариламина и их применения
US8680275B2 (en) 2009-10-23 2014-03-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
JP5759470B2 (ja) 2009-10-23 2015-08-05 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての二置換オクタヒドロピロロ［３，４−ｃ］ピロール
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物

Also Published As

Publication number Publication date
KR20140096338A (ko) 2014-08-05
AR088692A1 (es) 2014-06-25
TW201632517A (zh) 2016-09-16
IN2014CN04127A (es) 2015-07-10
CY1117638T1 (el) 2017-04-26
CL2014000659A1 (es) 2014-08-18
ES2572703T3 (es) 2016-06-01
JP2014532753A (ja) 2014-12-08
MX2014005635A (es) 2014-06-23
US9150566B2 (en) 2015-10-06
WO2013068935A1 (en) 2013-05-16
BR112014010617B1 (pt) 2021-12-14
ZA201404189B (en) 2017-08-30
JP5718535B2 (ja) 2015-05-13
EA024106B1 (ru) 2016-08-31
EA201400553A1 (ru) 2014-10-30
AU2012335194B2 (en) 2017-05-25
PL2776430T3 (pl) 2016-09-30
CA2846568C (en) 2020-01-14
NZ625896A (en) 2016-04-29
US20150158855A1 (en) 2015-06-11
BR112014010617A8 (pt) 2017-12-26
TW201323421A (zh) 2013-06-16
KR101676930B1 (ko) 2016-11-16
EP2776430A1 (en) 2014-09-17
AU2012335194A1 (en) 2014-07-03
CN103917538A (zh) 2014-07-09
HRP20160678T1 (hr) 2016-07-15
MY167791A (en) 2018-09-26
TWI555747B (zh) 2016-11-01
HUE029239T2 (en) 2017-02-28
HK1199022A1 (zh) 2015-06-19
IL232462A (en) 2016-11-30
EP2776430B1 (en) 2016-03-16
UA112317C2 (uk) 2016-08-25
CN103917538B (zh) 2016-08-24
DK2776430T3 (en) 2016-05-09
BR112014010617A2 (pt) 2017-04-25
TWI565703B (zh) 2017-01-11
SI2776430T1 (sl) 2016-06-30
CA2846568A1 (en) 2013-05-16
IL232462A0 (en) 2014-06-30
SG11201401665WA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
MX2014005635A (es) Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.
MY169986A (en) Benzimidazole-proline derivatives
PH12015501339A1 (en) Indole carboxamide derivatives as p2x7 receptor antagonists
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
PH12014501415A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
PH12015502632A1 (en) Cxcr7 receptor modulators
MX364610B (es) Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida.
MY176244A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
TN2016000061A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
PH12016500134B1 (en) 1-(piperazin-1-yl) -2- ([1,2,4] triazol -1- yl) - ethanone derivatives
UA112586C2 (uk) Похідні бензімідазолпроліну
TH156808A (th) อนุพันธ์ 2-(1,2,3-ไทรอะซอล-2อิล)เบนซาไมด์ และ 3-(1,2,3-ไทรอะซอล-2-อิล)พิโคลินาไมด์

Legal Events

Date Code Title Description
FG Grant or registration